Insinga, R. P., Laessig, R. H., & Hoffman, G. L. (2002). Newborn screening with tandem mass spectrometry: Examining its cost-effectiveness in the Wisconsin newborn screening panel. J Pediatr, 141(4), 524–531.
Association of Public Health Laboratories. The newborn screening story: How one simple test saved lives, science, and health in America [https://www.aphl.org/aboutAPHL/publications/Documents/NBS_2013May_The-Newborn-Screening-Story_How-One-Simple-Test-Changed-Lives-Science-and-Health-in-America.pdf] Accessed 2018 December 7
Advisory Committee on Heritable Disorders in Newborns and Children. Recommended Uniform Screening Panel [https://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/] Accessed 2017 May 1
Baby's First Test. Conditions Screened By State [http://www.babysfirsttest.org/newborn-screening/states] Accessed 2017 May 1.
Neumann, P. J., Goldie, S. J., & Weinstein, M. C. (2000). Preference-based measures in economic evaluation in health care. Annu Rev Public Health, 21(1), 587–611.
Kemper, A. R., Green, N. S., Calonge, N., Lam, W. K., Comeau, A. M., Goldenberg, A. J., Ojodu, J., Prosser, L. A., Tanksley, S., & Bocchini, J. A., Jr. (2013). Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's advisory committee on heritable disorders in newborns and children. Genet Med, 16(2), 183–187.
Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 2016.
Grosse, S.D. (2015). Showing value in newborn screening: Challenges in quantifying the effectiveness and cost-effectiveness of early detection of phenylketonuria and cystic fibrosis. Healthcare. 3(4), 1133-1157.
Brouwer, W. B., van Exel, N. J., van Gorp, B., & Redekop, W. K. (2006). The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Qual Life Res, 15(6), 1005–1021.
Prosser, L. A., Hammitt, J. K., & Keren, R. (2007). Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children. Pharmacoeconomics, 25(9), 713–726.
Prosser, L. A., Lamarand, K., Gebremariam, A., & Wittenberg, E. (2015). Measuring family HRQoL spillover effects using direct health utility assessment. Med Decis Mak, 35(1), 81–93.
Bobinac, A., Van Exel, N. J. A., Rutten, F. F., & Brouwer, W. B. (2011). Health effects in significant others: separating family and care-giving effects. Med Decis Mak, 31(2), 292–298.
Wittenberg, E., Saada, A., & Prosser, L. A. (2012). How illness affects family members: domains of well-being affected by "spillover". In The 34th Annual Meeting of the Society for Medical Decision Making: 2012 October 17-20 2012; Phoenix, AZ.
Wittenberg, E., & Prosser, L. A. (2013). Disutility of illness for caregivers and families: a systematic review of the literature. Pharmacoeconomics, 31(6), 489–500.
Knapp, A. A., Kemper, A. R., & Perrin, J. M. (2009). Evidence review: Krabbe disease.https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previousnominations/krabbe-disease-evidence-review-report.pdf. Accessed 8 January 2019.
Kemper, A. R., Knapp, A. A., Green, N. S., Comeau, A. M., Metterville, D. R., & Perrin, J. M. (2010). Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med, 12(9), 539–543.
Condtion Review Workgroup. Evidence Report: Newborn Screening for Pompe Disease [https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-external-evidence-review-report-2013.pdf] Accessed 2018 December 7.
Hunters Hope. Newborn screening- state and federal information [https://www.huntershope.org/newborn-screening/state-federal-information/] Accessed 2018 December 7
Prosser, L. A., Payne, K., Rusinak, D., Shi, P., Uyeki, T., & Messonnier, M. (2011). Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages. Value Health, 14(1), 135–143.
Prosser, L. A., Ray, G. T., O'Brien, M., Kleinman, K., Santoli, J., & Lieu, T. A. (2004). Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics, 113(2), 283–290.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York, NY: Oxford university press; 2015.
GfK (2013) KnowledgePanel Design Summary.
Kirsch IS. Adult literacy in America: A first look at the results of the National Adult Literacy Survey. Washington DC: ERIC; 1993.
Paasche-Orlow, M. K., Parker, R. M., Gazmararian, J. A., Nielsen-Bohlman, L. T., & Rudd, R. R. (2005). The prevalence of limited health literacy. J Gen Intern Med, 20(2), 175–184.
Arias, E. (2014). United States Life Tables, 2010. Natl Vital Stat Rep, 63(7), 1.
StataCorp. (2013). Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.
US Census Bureau. Profile of General Population and Housing Characteristics: 2010 Demographic Profile Data [https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk] Accessed 2018 December 7
Kanters, T. A., Redekop, W., Kruijshaar, M., van der Ploeg, A., Rutten-van Mölken, M., & Hakkaart, L. (2015). Comparison of EQ-5D and SF-6D utilities in Pompe disease. Qual Life Res, 24(4), 837–844.
Kanters, T. A., Hagemans, M. L., van der Beek, N. A., Rutten, F. F., van der Ploeg, A. T., & Hakkaart, L. (2011). Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis, 34(5), 1045–1052.
Hagemans, M., Janssens, A., Winkel, L., Sieradzan, K., Reuser, A., Van Doorn, P., & Van der Ploeg, A. (2004). Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology, 63(9), 1688–1692.
Kanters, T. A., Hoogenboom-Plug, I., Rutten-Van Mölken, M. P., Redekop, W. K., van der Ploeg, A. T., & Hakkaart, L. (2014). Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet J Rare Dis, 9(1), 75.
Bennett, J. E., Sumner, W., Downs, S. M., & Jaffe, D. M. (2000). Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med, 154(1), 43–48.
Prosser, L. A., Kong, C. Y., Rusinak, D., & Waisbren, S. L. (2010). Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics, 125(2), e286–e294.
Simon, E., Schwarz, M., Roos, J., Dragano, N., Geraedts, M., Siegrist, J., Kamp, G., & Wendel, U. (2008). Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes, 6(1), 25.
Bosch, A., Tybout, W., FJv, S., HWd, V., Wijburg, F., & Grootenhuis, M. (2007). The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis, 30(1), 29–34.
Landolt, M. A., Nuoffer, J.-M., Steinmann, B., & Superti-Furga, A. (2002). Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr, 140(5), 516–521.
Ubel, P. A., Loewenstein, G., & Jepson, C. (2003). Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res, 12(6), 599–607.
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., & Prosser, L. A. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA, 316(10), 1093–1103.
Kuhlthau, K., Kahn, R., Hill, K. S., Gnanasekaran, S., & Ettner, S. L. (2010). The well-being of parental caregivers of children with activity limitations. Matern Child Health J, 14(2), 155–163.
Poley, M. J., Brouwer, W. B., van Exel, N. J. A., & Tibboel, D. (2012). Assessing health-related quality-of-life changes in informal caregivers: an evaluation in parents of children with major congenital anomalies. Qual Life Res, 21(5), 849–861.
Prosser, L. A., Ladapo, J. A., Rusinak, D., & Waisbren, S. E. (2008). Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med, 162(9), 870–876.
Juniper, E., Guyatt, G., Feeny, D., Griffith, L., & Ferrie, P. (1997). Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. Eur Respir J, 10(10), 2285–2294.
Crump, R. T., Beverung, L. M., Lau, R., Sieracki, R., & Nicholson, M. (2016). Reliability, validity, and feasibility of direct elicitation of children’s preferences for health states a systematic review. Med Decis Making. https://doi.org/10.1177/0272989X16671925.
Grosse, S. D., Prosser, L. A., Asakawa, K., & Feeny, D. (2010). QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique. Expert Rev Pharmacoecon Outcomes Res, 10(3), 293–308.